Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.
Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg
February 3, 2021
January 28, 2021
Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and 30 mg
December 31, 2020
Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg
December 21, 2020
December 1, 2020
Search Result :-Is an investigational new drug that has not been approved for commercial distribution in the United States.
US Media Contact
For media inquiries only, please contact An Phan, Corporate Communications.
For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.